Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease November 8, 2024 — 17:45
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation September 14, 2024 — 08:18
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results August 29, 2024 — 14:31
Taicang Government and Fosun Tourism Group Jointly Launch Phase II Project of Taicang Alps Resort, Creating a World-class Ski Destination. June 18, 2024 — 23:50
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting June 2, 2024 — 13:19
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC June 2, 2024 — 08:24
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016 May 22, 2024 — 09:16
My Favourite International Design Awards 2024: Honoring Global Design Excellence March 5, 2024 — 10:44
Medtec China’s 20th Anniversary brings together 1000+ Exhibitors and Facilitates Business Innovation in Shanghai in September January 31, 2024 — 00:00
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma December 6, 2023 — 08:16
Charm of Jiangsu International Children’s Painting Exhibition was held in Paris, France July 13, 2023 — 22:38
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services July 7, 2023 — 21:00
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company July 5, 2023 — 23:07
An EV Assembled Within Two Hours! Gui’an Builds a Hi-tech High-end Manufacturing Base June 18, 2023 — 12:00
Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough June 5, 2023 — 11:51
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting June 4, 2023 — 08:36
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting June 4, 2023 — 02:15
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST June 3, 2023 — 07:59
CELL WORLD – Aiming at Internationalization, Starting from Regulation – The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held May 29, 2023 — 20:03
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference May 26, 2023 — 10:01
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma May 15, 2023 — 08:00
Crystal Formulation Services’ GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion May 12, 2023 — 21:00
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy May 10, 2023 — 08:00
The 2023 Bund Art Festival is Coming, Starting a One-stop Art Tour at the Great Yu Garden Area May 9, 2023 — 14:54
Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted May 6, 2023 — 21:00
Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List May 5, 2023 — 21:08
